More genetic markers for inherited testicular cancer identified

More genetic markers for inherited testicular cancer identified
A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited testicular germ cell tumors (TGCT) -- a 40 percent increase in the number of regions known to be associated with the cancer. The new findings, published online in Nature Communications, could help doctors understand which men are at the highest risk of developing the disease and signal them to screen those patients.


In 2017, the TECAC reported an additional 12 loci. The new study brings the total number to 78.

"This latest set of genetic locations is adding to our understanding of the inherited drivers of testicular cancer, as we look to improve screening among men who may be at high risk," Nathanson said. "Although this cancer is curable, identifying these men earlier can help save them from having to undergo certain treatments, such as chemotherapy, which can have late and unwanted complications."

Germ cell tumors account for 95 percent of testicular cancer cases. TGCTs are the most common cancer in the United States and Europe in white men between the ages of 20 and 39. The number of cases has continued to rise over the past 25 years in white men and more recently in Latino men. Despite significant evidence that susceptibility to these tumors is hereditary, CHEK2 is the only moderate penetrance gene in which pathogenic variants have been associated with risk of the cancer.

Genome-wide association studies (GWAS) have been more successful, identifying common variations associated with risk of the disease. Nathanson and TECAC teams have used the method to find locations on chromosomes -- called loci -- that contain variants associated with an increased risk of germ cell tumors.


In the latest study, TECAC researchers analyzed genetic data from 10,156 testicular germ cell tumor cases and 179,683 controls in the largest GWAS of TGCT to date.

The study revealed 22 novel loci. When taken together, the results can explain 44 percent of the father-to-son familial risk for testicular cancer, the authors said. Men with a high polygenic risk score (in the 95th percentile) also had a 6.8-fold increased disease risk compared to men at the median score.

Beyond the statistical significance of the new loci, the study also demonstrated two relevant biological pathways tied to disease susceptibility, male germ cell development and chromosomal segregation during cell division. When these pathways go awry, they lead to TGCT tumorigenesis.

"Results from our investigation provide further understanding of the genetic architecture of TGCT, enhance comprehension of the biology of male germ cell development, and highlight biological pathways specifically important to TGCT," the authors wrote. "Importantly, we have established a polygenic risk score that identifies men at highest risk of disease, which could be potentially applied in men with other risk factors, such as [undescended testes] or infertility, to be targeted for early detection and disease mitigation."

Next, researchers will begin to further investigate the increase in TGCT cases observed among Latino men and if the genetic variants observed in mostly white men also exist in that population.

Nathanson is a co-senior author on the study, along with Peter A. Kanetsky, PhD, MPH, of Moffitt Cancer Center.

TECAC is supported by the National Institutes of Health (U01 CA164947). The Penn GWAS study was supported by the Abramson Cancer Center (P30 CA016520) and the NIH (CA114478). This research was also supported in part by the California Cancer Research Program, and with awards from the Robert E. and May R. Wright Foundation and the Whittier Foundation.

Materials provided by . Note: Content may be edited for style and length.

University of Pennsylvania School of Medicine. "More genetic markers for inherited testicular cancer identified: A new meta-analysis increased the number of genetic locations for disease by 40 percent." ScienceDaily. ScienceDaily, 29 July 2021. .

University of Pennsylvania School of Medicine. "More genetic markers for inherited testicular cancer identified: A new meta-analysis increased the number of genetic locations for disease by 40 percent." ScienceDaily. (accessed July 29, 2021).



Mar. 24, 2021 — Sickle cell disease is the most prevalent inherited blood disorder in the world, affecting 70,000 to 100,000 Americans. However, it is considered an orphan disease, meaning it impacts less than ...

Jan. 7, 2020 — A massive genomewide analysis of approximately 200,000 military veterans has identified six genetic variants linked to ...

June 12, 2017 — An analysis of data from five major studies of testicular cancer has identified new genetic locations that could be susceptible to inherited testicular germ cell tumors. The findings, which ...

Dec. 28, 2016 — A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies. In mice, the substance kills degenerated cells and ...
News Topics :
An international group led by researchers from the RIKEN Center for Integrative Medical Sciences have used a combination of genome wide association analysis or GWAS and a trans ancestry comparison...
People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a...
Despite the rise in studies using polygenic risk scores, researchers have observed inconsistencies in how such scores are calculated and reported. These differences threaten to compromise the adoption of polygenic...
As genetic research continues to uncover loci, or areas in DNA, with specific changes that influence cancer risk, researchers can define polygenic risk scores PRS personalized estimates of an...
More than two thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as...